R K Karakulov
YOU?
Author Swipe
View article: Differentiated approach in the treatment of diffuse large B-cell lymphoma according to c-MYC and BCL2 status
Differentiated approach in the treatment of diffuse large B-cell lymphoma according to c-MYC and BCL2 status Open
Background . The treatment results of patients with diffuse large B-cell lymphoma (DLBCL) with c-MYC proto-oncogene and BCL2 protein positivity according to the CHOP-21 ± R scheme remain unsatisfactory, which dictates the need to intensify…
View article: Immune polychemotherapy regimen choice in B-cell non-Hodgkin lymphoma of high and low malignancy based on the identification of the mutational c-myc and BCL 2 genes
Immune polychemotherapy regimen choice in B-cell non-Hodgkin lymphoma of high and low malignancy based on the identification of the mutational c-myc and BCL 2 genes Open
Introduction: The relevance of research is conditioned by the study of the gene expression profile for the identification of molecular subgroups of non-Hodgkin B-cell lymphomas (NHBCLs) in haematology. Aim: The aim of this research was to …
View article: The history of oncohematology
development at the Kazakh Institute
of Oncology and Radiology
The history of oncohematology
development at the Kazakh Institute
of Oncology and Radiology Open
The article is devoted to the history of creation and development of the Oncohematology Department at the Kazakh Institute of Oncology and Radiology. For the first time, the authors
talk about the development of oncohematology at the Kaza…
View article: The history of oncohematology development
at the Kazakh Institute
of Oncology and Radiology
The history of oncohematology development
at the Kazakh Institute
of Oncology and Radiology Open
The article is devoted to the history of the creation and development of the Oncohematology Department at the Kazakh Institute of Oncology and Radiology (KazIOR).For the first time, the authors talk about the development of oncohematology …
View article: Treatment stratification of non-Hodgkin large B-cell lymphoma patients based on the identification of mutational c-MYC gene
Treatment stratification of non-Hodgkin large B-cell lymphoma patients based on the identification of mutational c-MYC gene Open
View article: PB1831 PRELIMINARY RESULTS OF THE COMBINED TREATMENT PRIMARY NON‐HODGKIN ORBITAL LYMPHOMAS
PB1831 PRELIMINARY RESULTS OF THE COMBINED TREATMENT PRIMARY NON‐HODGKIN ORBITAL LYMPHOMAS Open
Background: Non‐Hodgkin Lymphomas (NHL) effected organ of vision compose 8–12 % of all primary extranodal NHL, and may be the first and only sign of the disease. Aims: To estimate a therapy of patients with extranodal orbital lesion in our…
View article: PB2007 PRELIMINARY RESULTS OF USING BRENTUXIMAB VEDOTIN IN RELAPSE/REFRACTORY HODGKIN'S LYMPHOMA.
PB2007 PRELIMINARY RESULTS OF USING BRENTUXIMAB VEDOTIN IN RELAPSE/REFRACTORY HODGKIN'S LYMPHOMA. Open
Background: Hodgkin disease (HL) is curable disease in up to 80% of patients, but for the remaining relapse/refractory patients no standard salvage therapy exists. Brentuximab vedotin comprises an anti CD30 antibody conjugated by a proteas…
View article: Clinical Use of the Interferon Inducer IIBI in Patients with Refractory Hodgkin’s Lymphoma
Clinical Use of the Interferon Inducer IIBI in Patients with Refractory Hodgkin’s Lymphoma Open
This study evaluated the effects of the immunobiological preparation "Interferon inducer bacterial liquid" (IIBI) combined with chemoradiotherapy (CRT) in patients with refractory Hodgkin’s lymphoma (HL) are presented. The clinical applica…